SCHEMBL23218458

SCHEMBL23218458

NCc1cc(F)cc(-c2ccc3occ(Cc4cccc(CC(=O)O)c4O)c3c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 5/20 0.37
F11 P03951 2/20 0.37
TPSB2 P20231 2/20 0.37
PLAU P00749 2/20 0.37
PLG P00747 1/20 0.37
KLKB1 P03952 1/20 0.37
F7 P08709 1/20 0.37
SUCNR1 Q9BXA5 1/20 0.36
FFAR1 O14842 1/20 0.35
ALOX15 P16050 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR2C P28335 1/20 0.34
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592306 1.00 CFD (0.37) CFDF11TPSB2PLAUPLG
SCHEMBL23219088 0.83 ALOX15 (0.36) CFDSUCNR1FFAR1ALOX15KDM4E
SCHEMBL29591445 0.83 ALOX15 (0.36) CFDSUCNR1FFAR1ALOX15KDM4E
SCHEMBL29591346 0.81 CFD (0.54) CFDF11TPSB2PLAUPLG
SCHEMBL23219003 0.81 CFD (0.54) CFDF11TPSB2PLAUPLG
SCHEMBL23218502 0.81 CFD (0.54) CFDF11TPSB2PLAUPLG
SCHEMBL29591860 0.81 CFD (0.54) CFDF11TPSB2PLAUPLG
SCHEMBL29591167 0.73 CFD (0.52) CFDF11TPSB2PLAUPLG
SCHEMBL23218805 0.73 CFD (0.52) CFDF11TPSB2PLAUPLG
SCHEMBL23219040 0.72 CFD (0.57) CFDF11TPSB2PLAUPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885F11 24/4885TPSB2 419/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 14/4885TPSB2 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.